

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



China Grand Pharmaceutical and Healthcare Holdings Limited

遠大醫藥健康控股有限公司*
(incorporated in Bermuda with limited liability)
(Stock Code: 00512)

POSITIVE PROFIT ALERT

This announcement is made by China Grand Pharmaceutical and Healthcare Holdings Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of the directors (the “**Board**”) of the Company would like to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on the information currently available to the Company and the preliminary review by the management of the Company over the unaudited management accounts of the Group for the six months ended 30 June 2018, it is expected that the unaudited consolidated net profit attributable to owners of the Company recorded an increase of not less than 50% as compared to that of the six months ended 30 June 2017 (the unaudited consolidated net profit attributable to owners of the Company for the six months ended 30 June 2017 amounted to approximately HK\$205,905,000).

The Board believes that the reason for the significant increment is mainly attributable to (among other things) the mid-to-long term development strategy of the Group has steadily contributed significant returns, and the product categories of the core products are enlarged through internal research and development and also merge and acquisition. The competitiveness of our products is continuously enhanced, and the synergy effects of our products have been gradually revealed. These resulted the constant rapid growth of turnover and net profit. The bio-technology products of the Group have captured the opportunities available in the market, modified the product structure and enhanced the product quality in order to continuously improve the profitability. Furthermore, the companies acquired in last 2 years performed outstanding in operations and results. The returns from investments in 西安碑林藥業股份有限公司 (Xian Beilin Pharmaceutical Company Limited[#]) (which was acquired by the Group in the second half of 2016) and 北京九和藥業有限公司 (Beijing Jiu He Pharmaceutical Limited[#]) (which was acquired by the Group in 2015) have made significant growth as expected and continuously provide increasing contributions to the Group. All these factors are the major sources and basis for the continuous increment of the overall turnover amount of the Group.

The information contained in this announcement is only based on the preliminary review of the unaudited management accounts of the Group for the six months ended 30 June 2018 and the information currently available to the Board and such information has not been reviewed by the Company’s auditors or audit committee. The unaudited consolidated financial results of

the Group for the six months ended 30 June 2018 have not been finalized and may be subject to adjustment. The Company expects to publish an announcement on the interim results of the Group for the six months ended 30 June 2018 in August 2018.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
**China Grand Pharmaceutical and
Healthcare Holdings Limited**
Liu Chengwei
Chairman

Hong Kong, 12 July 2018

As at the date of this announcement, the Board comprises four executive directors, namely, Mr Liu Chengwei, Mr Hu Bo, Dr Shao Yan and Dr. Niu Zhanqi and two independent non-executive directors, namely, Ms So Tosi Wan, Winnie and Dr Pei Geng.

In this announcement, the English names of companies are unofficial translation or transliteration from their Chinese names and are for identification purposes only.

** For identification purpose only*